1. Home
  2. BFRG vs CMMB Comparison

BFRG vs CMMB Comparison

Compare BFRG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bullfrog AI Holdings Inc.

BFRG

Bullfrog AI Holdings Inc.

N/A

Current Price

$1.00

Market Cap

13.1M

Sector

Technology

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$2.10

Market Cap

13.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BFRG
CMMB
Founded
2017
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.1M
13.8M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
BFRG
CMMB
Price
$1.00
$2.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
65.3K
96.6K
Earning Date
11-14-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,670.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$2.01
52 Week High
$4.84
$9.84

Technical Indicators

Market Signals
Indicator
BFRG
CMMB
Relative Strength Index (RSI) 41.06 33.84
Support Level $1.10 $2.01
Resistance Level $1.21 $2.77
Average True Range (ATR) 0.07 0.21
MACD 0.01 -0.04
Stochastic Oscillator 13.97 17.28

Price Performance

Historical Comparison
BFRG
CMMB

About BFRG Bullfrog AI Holdings Inc.

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: